# Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

Study · id `cardio:ct-nct01106131` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01106131](<https://clinicaltrials.gov/study/NCT01106131>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01106131

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

## Technical summary

Registry record NCT01106131. Randomized; triple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 253 participants (enrolled count; ClinicalTrials.gov record NCT01106131, source copy `cardio:ctgov-nct01106131-2013-02-15`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01106131, source copy `cardio:ctgov-nct01106131-2013-02-15`, retrieved 2026-10-26)
- Primary completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01106131, source copy `cardio:ctgov-nct01106131-2013-02-15`, retrieved 2026-10-26)
- Completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01106131, source copy `cardio:ctgov-nct01106131-2013-02-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01106131, source copy `cardio:ctgov-nct01106131-2013-02-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01106131-2013-02-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): CKD-501 0.5mg
- Intervention (Drug): Pioglitazone 15mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: 902dd51bbc79913bf2b74b251492cdab437b1d98e5aa4f9503b3dcedcabedf52
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
